Bruker Corporation
A maker of high-performance scientific instruments, Bruker builds the NMR, mass spectrometry, X-ray, and microscopy tools that researchers use to study molecules, cells, and materials, plus superconducting wire for MRI and fusion energy. It was founded in 1960 in a backyard workshop in Karlsruhe, Germany, by physicist Günther Laukien and Dr. Emil Bruker. The company carries Bruker's name because German rules barred professors from commercializing their research, so Laukien couldn't be listed as a founder.
6.375% Preferred Stock Series A
10-Q · Quarter ended Jun 30, 2026 · SEC filing ↗
A $134.9 million charge pushed Bruker to a operating loss this quarter. rose 5.2% to $838.5 million and expanded to 52.1% as cost savings and a positive net tariff impact took hold, but the erased those gains on the . The underlying business is improving, but the shows the cost of past acquisitions is still being reckoned with.
Q2 2026 revenue rose 5.2% to $838.5M driven by biopharma and semiconductor demand, but GAAP operating loss of $65.3M resulted from $134.9M in goodwill impairments.
Information concerning market risk is contained in Item 7A “Quantitative and Qualitative Disclosures About Market Risk” in our 2025 Form 10-K. As of June 30, 2026, there were no material changes in our exposure to market risk from December 31, 2025.
Information concerning market risk is contained in Item 7A “Quantitative and Qualitative Disclosures About Market Risk” in our 2025 Form 10-K. As of June 30, 2026, there were no material changes in our exposure to market risk from December 31, 2025.
Read original filing text →We are involved in lawsuits, claims, and proceedings, including, but not limited to, patent, customer, labor and employment, and commercial matters, which arise in the ordinary course of business. As of June 30, 2026, other than as disclosed in Note 20, Commitments and Contingen…
We are involved in lawsuits, claims, and proceedings, including, but not limited to, patent, customer, labor and employment, and commercial matters, which arise in the ordinary course of business. As of June 30, 2026, other than as disclosed in Note 20, Commitments and Contingencies in the Notes to our unaudited condensed consolidated financial statements in this Quarterly Report on Form 10-Q, the Company is not party to any material pending legal proceedings other than ordinary routine litigation incidental to the Company’s business, to which the Company or any of its subsidiaries is a party or of which any of their property is the subject. However, the outcome of any of these proceedings cannot be accurately predicted, and the ultimate resolution of any of these existing matters may have a material adverse effect on the Company's business or financial condition. In addition, we are subject to regulation by national, state and local government agencies in the United States and other countries in which we operate. From time to time, we are the subject of governmental investigations often involving regulatory, marketing and other business practices. These governmental investigations may result in the commencement of civil and criminal proceedings, fines, penalties, and administrative remedies which could have a material adverse effect on our financial position, results of operations and/or liquidity.
Read original filing text →In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our 2025 Form 10-K, which could materially affect our business, financial condition or future results.…
In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our 2025 Form 10-K, which could materially affect our business, financial condition or future results. The risks described in this Quarterly Report on Form 10-Q and in our 2025 Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results.
Read original filing text →